|  | All patients (n = 153) | Without HSV reactivation (n = 113) | HSV reactivation (n = 40) | p-value |
---|---|---|---|---|---|
Female | Number (%) | 38 (24.8) | 28 (24.8) | 10 (25) | 1.000 |
Age | Median (IQR) | 60.8 [50.2; 69.5] | 60.8 [50.1; 68.8] | 61.9 [50.9; 70.8] | 0.546 |
BMI | Median (IQR) | 28.8 [25.3; 33] | 29 [25.4; 33] | 27.7 [24.4; 33.2] | 0.629 |
Diabetes | Number (%) | 48 (31.4) | 40 (35.4) | 8 (20) | 0.078 |
Other chronic diseases* | Number (%) | 73 (47.7) | 55 (48.7) | 18 (45) | 0.716 |
SOFA score | Median (IQR) | 5 [3; 7] | 5 [3; 7] | 5 [4; 7] | 0.468 |
Maximal body temperature (°C) | Median (IQR) | 38.2 [37.5; 39.1] | 38 [37.5; 39] | 38.9 [37.8; 39.3] | 0.029 |
Mechanical ventilation | Â | Â | Â | Â | 0.009 |
None | Number (%) | 16 (10.5) | 14 (12.4) | 2 (5) | Â |
CPAP/HFNO | Number (%) | 85 (55.6) | 69 (61.1) | 16 (40) | Â |
IMV/PEEP < 10 mmHg | Number (%) | 0 | 0 | 0 |  |
IMV/PEEP > 10 mmHg | Number (%) | 40 (26.1) | 22 (19.5) | 18 (45) |  |
ECMO | Number (%) | 12 (7.8) | 8 (7.1) | 4 (10) | Â |
Lymphocytes count (/mm3) | Median (IQR) | 885 [595; 1220] | 890 [610; 1230] | 880 [570; 1210] | 0.784 |
Initial use of corticosteroid | Number (%) | 108 (70.6) | 86 (76.1) | 22 (55) | 0.016 |
Tocilizumab/anakinra | Number (%) | 31 (20.3) | 25 (22.1) | 6 (15) | 0.492 |
CRP (mg/L) | Median (IQR) | 138.5 [77.5; 204.5] | 125 [64.5; 183.5] | 180.5 [115.5; 252.5] | 0.001 |
D-Dimers (mg/mL) | Median (IQR) | 962 [588; 2043] | 952 [564; 1768] | 1056.5 [682; 4376] | 0.195 |
Ferritin (ng/mL) | Median (IQR) | 1159 [592; 1979] | 1060 [526; 1915] | 1348 [832; 2370] | 0.110 |
LDH (UI/L) | Median (IQR) | 438.5 [337; 606.9] | 417 [331; 538] | 504.9 [388; 695] | 0.019 |